Table 1.
List of clinical trials combining antiangiogenic therapies and immunotherapies.
| Tumor Type | Clinical Trial ID | AAT | IT | Other therapies included in the combinationa |
|---|---|---|---|---|
| Malignant Solid Tumor | NCT02857920 | Bevacizumab | Allogenic NK therapy | No |
| Hepatocellular carcinoma/Bilary tract cancer | NCT04518852 | Sorafenib | PD-1 mAbb | Yes |
| NCT04273100 | Lenvatinib | PD-1 mAbb | Yes | |
| NCT05313282 | Apatinib | Camrelizumab | Yes | |
| NCT05775159 |
Bevacizumab Lenvatinib |
MEDI5752 | Yes | |
| NCT05665348 | Bevacizumab |
Atezolizumab Ipilimumab |
No | |
| NCT05750030 | Bevacizumab | Atezolizumab | Yes | |
| NCT04191889 | Apatinib | Camrelizumab | Yes | |
| NCT05052099 | Bevacizumab |
Atezolizumab RP3 |
No | |
| NCT05733598 | Bevacizumab | Atezolizumab | Yes | |
| NCT03937830 | Bevacizumab |
Durvalumab Tremelimumab |
Yes | |
| NCT02519348 | Bevacizumab |
Durvalumab Tremelimumab |
Yes | |
| NCT05359861 | Bevacizumab |
Atezolizumab SRF388 |
No | |
| Ovarian cancer | NCT04928583 | Bevacizumab | Oregovomab | Yes |
| NCT02759588 | Bevacizumab | GL-ONC1 | No | |
| NCT03197584 | Bevacizumab | Avelumab | Yes | |
| NCT05281471 | Bevacizumab | Olvimulogene nanivacirepvec | Yes | |
| Gastrointestinal cancer | NCT04069273 | Ramucirumab | Pembrolizumab | Yes |
| Lung cancer | NCT05360979 | Recombinant human endostatin | Envafolimab | Yes |
| NCT05529355 | Endostar | Envafolimab | Yes | |
| NCT04459078 | Apatinib | Camrelizumab | Yes | |
| NCT03280563 | Bevacizumab | Atezolizumab | Yes | |
| NCT05781308 | Bevacizumab | Atezolizumab | No | |
| NCT05782764 | Endostar | ICBb | Yes | |
| NCT04303130 | Endostar | Camrelizumab | No | |
| NCT03169738 | Bevacizumab | Avelumab | Yes | |
| NCT02039674 | Bevacizumab | Pembrolizumab | Yes | |
| Pancreatic cancer | NCT05298020 | Endostar | Envafolimab | Yes |
| NCT03136406 | Bevacizumab | Severalc | Yes | |
| NCT03329248 | Bevacizumab | Avelumab | Yes | |
| NCT03387098 | Bevacizumab | Several | Yes | |
| NCT03193190 | Bevacizumab | Several | Yes | |
| Breast cancer | NCT04877821 | Anlotinib | Sintilimab | No |
| NCT03395899 | Bevacizumab | Atezolizumab | Yes | |
| NCT0518006 | Bevacizumab | Atezolizumab | No | |
| NCT03175666 | Bevacizumab | Avelumab | Yes | |
| NCT04739670 | Bevacizumab | Atezolizumab | Yes | |
| NCT03387085 | Bevacizumab | Severalc | Yes | |
| Colorectal cancer | NCT03169777 | Bevacizumab | Severalc | Yes |
| NCT04262687 | Bevacizumab | Pembrolizumab | Yes | |
| NCT03950154 | Bevacizumab | PD-1-T cell | Yes | |
| NCT04017455 | Bevacizumab | Atezolizumab | No | |
| NCT05733611 | Bevacizumab | Atezolizumab | Yes | |
| NCT04527068 | Bevacizumab | Tripleitriumab | No | |
| NCT04194359 | Bevacizumab | Sintilimab | No | |
| Blood cancer | NCT03169790 | Bevacizumab | Avelumab | Yes |
| NCT03167177 | Bevacizumab | Avelumab | Yes | |
| Nasopharyngeal cancer | NCT03813394 | Bevacizumab | Pembrolizumab | No |
| GBM | NCT04952571 | Bevacizumab | Camrelizumab | No |
| Skin cancer | NCT03167164 | Bevacizumab | Avelumab | Yes |
| NCT03387111 | Bevacizumab | Several | Yes | |
| Urothelial cancer | NCT03197571 | Bevacizumab | Avelumab | Yes |
| Head and Neck Squamous Cell Carcinoma | NCT03193190 | Bevacizumab | Avelumab | Yes |
AAT anti-angiogenic therapies; IT immunotherapy.
Clinical trials are included if the trial title mentions a combination of AAT and IT. Resource: http://clinicaltrials.gov.
aOther therapies include chemotherapy and transarterial chemoembolization.
bSpecific therapeutics used are not clarified.
cMore than two types of immunotherapies were utilized.